Facts & Figures

12.2 bn
Sales / Year
Source: Vienna Life Science Report 2017/18 (Data: 2017) More Information

Are you up to date?


ÖVIH: Impfstoffhersteller fordern Nationalen Aktionsplan

7-Punkte-Plan zur Erhöhung der Durchimpfungsraten

HOOKIPA: HOOKIPA Pharma Announces Pricing of Initial Public Offering

HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics, targeting infectious diseases...

Boehringer Ingelheim: Financial year 2018: Boehringer Ingelheim grows and invests

•Well-filled research pipeline in oncology, fibrotic diseases, immunology and metabolic diseases

•Operating growth...

All news

Driven by curiosity, inspired by our city...

Twitter @lifesciencevie



AUSTROMED Seminar: Medizinproduktegesetz

Grundlagen und Entstehungsgeschichte der Europäischen Medizinproduktegesetzgebung


Pharmig Academy: Zertifikatslehrgang Quality First, Modul 2

Kundenaudits & Behördeninspektionen: Das QMS (Quality Management System) auf dem Prüfstand

30.4. - 1.5.2019
International meeting


BioTrinity 2019

Europe’s leading biopartnering and investment conference

All events

Why Vienna?

Philipp von Lattorff - Boehringer Ingelheim
(C) Boehringer Ingelheim / Marion Carniel

Political stability is a major factor when considering major investments in a country. Austria scores very highly in that regard, as it does in terms of infrastructure and standard of living. Without a doubt, however, one of the most important considerations for a research-driven company is research subsidies. This also played a decisive role in the decision to invest 700 million euros in the construction of our new biopharmaceutical production facility in Vienna. We are looking for highly qualified candidates to fill the 500 new positions, created for this project, and attach great importance for that reason to the training and qualifications of potential employees.

Philipp von Lattorff
Managing Director at Boehringer Ingelheim RCV GmbH & Co KG